2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 659

Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Abstract Number: 1129

Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Abstract Number: 1598

Disability Among Subtypes of SLE
Abstract Number: 1923

Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
Abstract Number: 1438

Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Abstract Number: 521

Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Abstract Number: 2370

Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Abstract Number: 1385

Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Abstract Number: 965

Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases
Abstract Number: 36

Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Abstract Number: 1925

Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis
Abstract Number: 1612

Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
Abstract Number: 1588

Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?
Abstract Number: 1726

Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study
Abstract Number: 440

Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].